Clinical Trial: A Phase IV Study to Evaluate Safety, Tolerability and Effectiveness of Rivastigmine Patch 15cm2 in Patients With Severe Dementia of the Alzheimer's Type.
Study Status: Not yet recruiting
Recruit Status: Not yet recruiting
Study Type: Interventional
Official Title: A Prospective, 16 Week, Phase IV Study to Evaluate Safety, Tolerability and Effectiveness in Patients With Severe Dementia of the Alzheimer's Type Exposed to Rivastigmine (Exelon)15Same as current
Current Secondary Outcome: changes in Mini-Mental State Examination (MMSE [ Time Frame: 16 weeks ]
Original Secondary Outcome: Same as current
Information By: Novartis
Dates:
Date Received: December 8, 2016
Date Started: May 31, 2017
Date Completion: August 31, 2018
Last Updated: February 19, 2017
Last Verified: February 2017